FacebookTwitterGoogle+RedditEmail

Big Pharma’s Profiteers: You Want Us to Pay What for These Meds?

It is no secret that the pill profit party is over for drug companies. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular, Concerta, Cymbalta and Abilify have gone off patent and Wall Street is moving on to industries that offer better returns.

To combat investor disenchantment, drug companies have rolled out expensive drugs that treat such rare conditions,  they almost sound like satire. If you are sleepy during the day, you may have narcolepsy says Jazz Pharmaceuticals which its drug Xyrem treats for $35,000 per year.  If you have frequent diarrhea, gas and bloating, you may have exocrine pancreatic insufficiency says AbbVie to sell the drug Creon.

Drug makers are even not above scaring the populace if it sells drugs for rare diseases. Your back pain may not be from working out at all but from a disease called ankylosing spondylitis, says AbbVie, a condition that can be treated with its biologic drug Humira for as much as $20,000 a year. (Injectable “biologic” drugs are a new drug industry push because they are so expensive and less susceptible to generic competition than pills.)

The drug industry is also trying to stay a Wall Street darling with new, uber priced drugs—notably hepatitis C drugs. Gilead Sciences sold $12.4 billion worth of Sovaldi at $1000 a pill last year, reports the New York Timesstraining the budgets of insurance companies and Medicaid programs.”

While drug company representatives initially tried to cast the outrageous prices as recouping martharosenbergtheir research and development costs they quickly back pedaled into admitting the drugs are priced on “value”—what they are “worth” for the patient’s health. Needless to say such valuations come pretty close to the definition of extortion—or offers you “can’t refuse.”

Even business writers cry foul. Why does the same hepatitis C drug that costs $84,000 a year in the US cost $900 a year in Egypt asked Forbes staff writer Avik Roy. Since most hepatitis C patients in the US are uninsured, underinsured or imprisoned, taxpayers pick up the bill through Medicaid, the VA and prison systems writes Roy.

Now Sanofi and Regeneron Pharmaceuticals are rolling out a cholesterol lowering drug which could be embraced by the millions who made the statin Lipitor the best selling drug in the world before it went off patent. Yet the list price of Praluent, an injectable biologic, is over $14,600 a year.  Like Gilead, Sanofi and Regeneron say the price reflects what it is worth in potential benefits to patients and savings to the health care system—e.g. what they can get.

Nor is cost the only question with the new cholesterol drug. Increasingly, high bad cholesterol is viewed as a weak cardiovascular risk factor versus other factors like inflammation. Cholesterol lowering drugs can also be used to duck important lifestyle changes. “Plenty of adults down statins regularly and shine off healthy eating because they know a cheeseburger and steak can’t fool a statin,” writes Dr. Michael J. Breus on the Huffington Post.

Luckily, lawmakers are demanding cost breakdowns from drug companies on the new four-digit priced drugs.  How much are true costs and what is profiteering? Some states are drafting bills that would allow insurers to refuse to pay for a drug if the manufacturer did not file the required cost breakdown reports.

What is the response of drug makers to bills addressing expensive drugs?  They would be costly to comply with, they say.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

November 12, 2018
Kerron Ó Luain
Poppy Fascism and the English Education System
Conn Hallinan
Nuclear Treaties: Unwrapping Armageddon
Robert Hunziker
Tropical Trump Declares War on Amazonia
John W. Whitehead
Badge of Shame: the Government’s War on Military Veterans
Will Griffin
Military “Service” Serves the Ruling Class
John Eskow
Harold Pinter’s America: Hard Truths and Easy Targets
Rob Okun
Activists Looking Beyond Midterm Elections
Binoy Kampmark
Mid-Term Divisions: The Trump Take
Dean Baker
Short-Term Health Insurance Plans Destroy Insurance Pools
George Wuerthner
Saving the Buffalohorn/Porcupine: the Lamar Valley of the Gallatin Range
Patrick Howlett-Martin
A Note on the Paris Peace Forum
Joseph G. Ramsey
Does America Have a “Gun Problem”…Or a White Supremacy Capitalist Empire Problem?
Weekend Edition
November 09, 2018
Friday - Sunday
Louis Proyect
Why Democrats Are So Okay With Losing
Andrew Levine
What Now?
Jeffrey St. Clair
Roaming Charges: Chuck and Nancy’s House of Cards
Brian Cloughley
The Malevolent Hypocrisy of Selective Sanctions
Marc Levy
Welcome, Class of ‘70
David Archuleta Jr.
Facebook Allows Governments to Decide What to Censor
Evaggelos Vallianatos
The Zika Scare: a Political and Commercial Maneuver of the Chemical Poisons Industry
Nick Pemberton
When It Comes To Stone Throwing, Democrats Live In A Glass House
Ron Jacobs
Impeach!
Lawrence Davidson
A Tale of Two Massacres
José Tirado
A World Off Balance
Jonah Raskin
Something Has Gone Very Wrong: An Interview With Ecuadoran Author Gabriela Alemán
J.P. Linstroth
Myths on Race and Invasion of the ‘Caravan Horde’
Dean Baker
Good News, the Stock Market is Plunging: Thoughts on Wealth
David Rosen
It’s Time to Decriminalize Sex Work
Dan Glazebrook
US Calls for a Yemen Ceasefire is a Cynical Piece of Political Theatre
Jérôme Duval
Forced Marriage Between Argentina and the IMF Turns into a Fiasco
Jill Richardson
Getting Past Gingrich
Dave Lindorff
Not a Blue Wave, But Perhaps a Foreshock
Martha Rosenberg
Dangerous, Expensive Drugs Aggressively Pushed? You Have These Medical Conflicts of Interest to Thank
Will Solomon
Not Much of a Wave
Nicolas J S Davies
Why Yemeni War Deaths are Five Times Higher Than You’ve Been Led to Believe
Jim Goodman
We call BS! Now, Will You Please Get Over This Partisanship?
Josh Hoxie
How Aristocracies are Born
Faisal Khan
The Weaponization of Social Media
James Munson
The Left Has Better Things to Do Than Watch Liberals Scratch Their Heads
Kenneth Culton
The Political Is Personal
Graham Peebles
Fracking in the UK
Alycee Lane
The Colonial Logic of Geoengineering’s “Last Resort”
Kevin Basl
How Veterans Changed the Military and Rebuilt the Middle Class
Thomas Knapp
Election 2018: The More Things Don’t Change, the More They Stay the Same
Gary Leupp
Europe and Secondary Iran Sanctions: Where Do We Go Now?
Saurav Sarkar
An Honest Look at Poverty in the Heartland
FacebookTwitterGoogle+RedditEmail